It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?
Venture capital’s refusal to continue support helped Cyan Technology into liquidation. Rebuilt by its management, Cyan is now wary of asking VCs for money.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.